卡他莫拉菌对新型四环素药物Eravacylcine的敏感性分析
|
摘要
目的探索卡他莫拉菌对新型四环素类抗菌药物Eravacylcine的敏感性,并对卡他莫拉菌四环素类抗菌药物耐药机制进行初步研究。方法收集深圳市南山区人民医院2012—2017年临床分离出的卡他莫拉菌菌株,所有的菌株均通过BD细菌自动鉴定仪鉴定,同时采用质谱仪鉴定细菌种属。采用琼脂平板稀释法检测多西环素、米诺环素、Eracycline的药物MIC值(最小抑菌浓度)。提取卡他莫拉菌菌株基因组DNA,同时采用PCR方法检测了四环素耐药相关基因tetB、tetM、tetW、tetQ、tetO和tetT。结果本研究共收集了207株卡他莫拉菌,在痰液和咽拭子中检出率最高,各占77.8%、20.8%;科室分布以儿科为主,占78.7%,其次为呼吸科,占8.9%。207株卡他莫拉菌对四环素类抗菌药物表现出较高的敏感性,以EUCAST判定标准,米诺环素敏感率为98%,多西环素敏感率为97%,新型四环素类抗菌药物Eravacycline的MIC值基本在0.5 mg/L以下。207株细菌中共检测出tetB阳性菌株136株。结论卡他莫拉菌对四环素类抗菌药物尤其是新型四环素类抗菌药物Eravacycline具有较好的敏感性,但关于卡他莫拉菌四环素类抗菌药物耐药机制仍需进一步研究。
Objective To study the susceptibility of new tetracycline drug eravacylcine and to conduct a preliminary study on the mechanism of tetracycline resistance in M. catarrhalis from our hospital. Methods We collected the M.catarrhalis clinical strains that identified by BD automatic analyzer in hospital from 2012 to 2017, all the strains were classified for specie by mass spectrometry. The MICs(Minimum inhibitory concentration) value of doxycycline, minocycline, eracycline were tested by agar plate dilution method. Then we extracted the genomic DNA of M. catarrhalis strain, and detected the drugresistant genes(tetB, tetM, tetW, tetQ, tetO, tetT) by PCR(polymerase chain reaction). Results A total of 207 strains of M.catarrhalis were collected in our study, with the highest detection rates in sputum and throat swabs, accounting for 77.8% and 20.8%, respectively; the detection rate of Department of Pediatrics and Department of Respiratory were 78.7% and 8.9 %.According to the European Committee on Antimicrobial Susceptibility Testing(EUCAST) criteria of M. catarrhalis, the sensitivity rates of M. catarrhalis on minocycline and doxycycline were 98% and 97%. The MIC values of M. catarrhalis on new tetracycline antibiotic eravacycline were almost below 0.5 mg/L. And 136 strains of tetB positive strains were detected in our study. Conclusion The tetracycline antibiotics have good sensitivity on M. catarrhalis, especially the new tetracycline drug eravacycline. However, the mechanism of tetracycline resistance in Moraxella catarrhalis still needs further study.
Objective To study the susceptibility of new tetracycline drug eravacylcine and to conduct a preliminary study on the mechanism of tetracycline resistance in M. catarrhalis from our hospital. Methods We collected the M.catarrhalis clinical strains that identified by BD automatic analyzer in hospital from 2012 to 2017, all the strains were classified for specie by mass spectrometry. The MICs(Minimum inhibitory concentration) value of doxycycline, minocycline, eracycline were tested by agar plate dilution method. Then we extracted the genomic DNA of M. catarrhalis strain, and detected the drugresistant genes(tetB, tetM, tetW, tetQ, tetO, tetT) by PCR(polymerase chain reaction). Results A total of 207 strains of M.catarrhalis were collected in our study, with the highest detection rates in sputum and throat swabs, accounting for 77.8% and 20.8%, respectively; the detection rate of Department of Pediatrics and Department of Respiratory were 78.7% and 8.9 %.According to the European Committee on Antimicrobial Susceptibility Testing(EUCAST) criteria of M. catarrhalis, the sensitivity rates of M. catarrhalis on minocycline and doxycycline were 98% and 97%. The MIC values of M. catarrhalis on new tetracycline antibiotic eravacycline were almost below 0.5 mg/L. And 136 strains of tetB positive strains were detected in our study. Conclusion The tetracycline antibiotics have good sensitivity on M. catarrhalis, especially the new tetracycline drug eravacycline. However, the mechanism of tetracycline resistance in Moraxella catarrhalis still needs further study.
引文
[1] EARL J P, DE VRIES S P W, AHMED A, et al. Comparative genomic analyses of themoraxella catarrhalisserosensitive and seroresistant lineages demonstrate their independent evolution[J]. Genome Biology and Evolution, 2016, 8(4):955-974.
[2]杨晓华,王桂兰,汪伟山,等.儿童呼吸道卡他莫拉菌感染状况及耐药性和耐药基因的研究[J].国外医药(抗生素分册), 2017, 38(2):72-75.
[3] SHAIKH S, ARSALAN S A, AHMED Z, et al. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections[J]. Infection and Drug Resistance, 2015:263.
[4] LIU Y L, XIAO M, CHENG J W, et al. Moraxella catarrhalis macrolide-resistant isolates are highly concentrated in two MLST clonal complexes-CCN10 and CC363[J]. Frontiers in Microbiology, 2017,8:201.
[5]林爱心,谭南,杨晓华,等. 997例卡他莫拉菌的分布情况及药物敏感性分析[J].国际检验医学杂志, 2016,(3):376-377.
[6] SUTCLIFFE J A, O'BRIEN W, FYFE C, et al. Antibacterial activity of eravacycline(TP-434), a novel fluorocycline, against hospital and community pathogens[J]. Antimicrobial Agents and Chemotherapy,2013, 57(11):5548-5558.
[7] ZHANEL G G, CHEUNG D, ADAM H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent[J]. Drugs, 2016, 76(5):567-588.
[8]郑红艳,宋文琪,董方,等.儿童患者中分离189株卡他莫拉菌的分布和耐药性分析[J].中国感染与化疗杂志,2016,16(5):614-617.
[9]郭静,李从荣. 2013—2016年某大型综合性医院呼吸道感染常见菌的耐药性分析[J].公共卫生与预防医学, 2018, 29(6):44-47.
[10] NGUYEN F, STAROSTA A L, ARENZ S, et al. Tetracycline antibiotics and resistance mechanisms[J]. Biol Chem, 2014, 395(5):559-575.
[11] NGUYEN F, STAROSTA A L, ARENZ S, et al. Tetracycline antibiotics and resistance mechanisms[J]. Biol Chem, 2014, 395(5):559-575.
[12] CHOPRA I, ROBERTS M. Tetracycline antibiotics:mode of action,applications, molecular biology, and epidemiology of bacterial resistance[J]. Microbiology and Molecular Biology Reviews, 2001, 65(2):232-260.
[13]代敏,王雄清,殷桂兰.四环素耐药基因的生化和遗传机制研究进展[J].绵阳师范学院学报, 2006, 25(5):72-78.
[14] VILLEDIEU A, DIAZ-TORRES M L, HUNT N, et al. Prevalence of tetracycline resistance genes in oral bacteria[J]. Antimicrobial Agents and Chemotherapy, 2003, 47(3):878-882.
[2]杨晓华,王桂兰,汪伟山,等.儿童呼吸道卡他莫拉菌感染状况及耐药性和耐药基因的研究[J].国外医药(抗生素分册), 2017, 38(2):72-75.
[3] SHAIKH S, ARSALAN S A, AHMED Z, et al. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections[J]. Infection and Drug Resistance, 2015:263.
[4] LIU Y L, XIAO M, CHENG J W, et al. Moraxella catarrhalis macrolide-resistant isolates are highly concentrated in two MLST clonal complexes-CCN10 and CC363[J]. Frontiers in Microbiology, 2017,8:201.
[5]林爱心,谭南,杨晓华,等. 997例卡他莫拉菌的分布情况及药物敏感性分析[J].国际检验医学杂志, 2016,(3):376-377.
[6] SUTCLIFFE J A, O'BRIEN W, FYFE C, et al. Antibacterial activity of eravacycline(TP-434), a novel fluorocycline, against hospital and community pathogens[J]. Antimicrobial Agents and Chemotherapy,2013, 57(11):5548-5558.
[7] ZHANEL G G, CHEUNG D, ADAM H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent[J]. Drugs, 2016, 76(5):567-588.
[8]郑红艳,宋文琪,董方,等.儿童患者中分离189株卡他莫拉菌的分布和耐药性分析[J].中国感染与化疗杂志,2016,16(5):614-617.
[9]郭静,李从荣. 2013—2016年某大型综合性医院呼吸道感染常见菌的耐药性分析[J].公共卫生与预防医学, 2018, 29(6):44-47.
[10] NGUYEN F, STAROSTA A L, ARENZ S, et al. Tetracycline antibiotics and resistance mechanisms[J]. Biol Chem, 2014, 395(5):559-575.
[11] NGUYEN F, STAROSTA A L, ARENZ S, et al. Tetracycline antibiotics and resistance mechanisms[J]. Biol Chem, 2014, 395(5):559-575.
[12] CHOPRA I, ROBERTS M. Tetracycline antibiotics:mode of action,applications, molecular biology, and epidemiology of bacterial resistance[J]. Microbiology and Molecular Biology Reviews, 2001, 65(2):232-260.
[13]代敏,王雄清,殷桂兰.四环素耐药基因的生化和遗传机制研究进展[J].绵阳师范学院学报, 2006, 25(5):72-78.
[14] VILLEDIEU A, DIAZ-TORRES M L, HUNT N, et al. Prevalence of tetracycline resistance genes in oral bacteria[J]. Antimicrobial Agents and Chemotherapy, 2003, 47(3):878-882.